Tirzepatide combines the actions of both a GLP-1 receptor agonist and a glucose-dependent insulinotropic polypeptide receptor agonist. Basically, this dual action helps control blood sugar in multiple ways, making it different from traditional GLP-1 agonists like semaglutides. Typically,
results are quicker and/or slightly stronger.